Citations

Clear

6273 citation(s) found for "To, Andrew".

Aurora-A overexpression is linked to development of aggressive teratomas derived from humans iPS cells
Ohmine, Seiga, Salisbury, Jeffrey L., Pettinato, Giuseppe , Haddad, Tufia C. , D’Assoro, Antonino B. , Ingle, James, Haddad, Tufia, Galanis, Evanthia , D'Assoro, Antonino B, Ingle, James N. , Haddox, Candace L. , Ikeda, Yasuhiro

Mayo Clinic

Oncology Reports | January 31, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3892/or.2018.6239 | PMID 29393405 Get It

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
Dingli, David , Cornell, Robert F. , Huff, Carol Ann , Bhutani, Divaya , Zonder, Jeffrey A. , Cole, Craig E. , Vij, Ravi , Abonour, Rafat , Schiller, Gary J. , Parker, Terri L., Costa, Luciano J. , Kaminetzky, David , Hoffman, James E. , Chari, Ajai , Wier, Scott Van, Ahmann, Gregory , Lopez, Ilsel, Kauffman, Michael , Shacham, Sharon, Saint-Martin, Jean-Richard, Picklesimer, Carla, Choe-Juliak, Cassandra, Stewart, A. Keith, Vogl, Dan T. , Cornell, Robert Frank, Zonder, Jeffrey, Nooka, Ajay, Richter, Joshua , Cole, Craig, Schiller, Gary, Yee, Andrew J. , Van Wier, Scott, Picklesimer, Carla D, Chari, Ajai , Dingli, David , Bhutani, Divaya , Costa, Luciano J , Jagannath, Sundar , Baz, Rachid , Nooka, Ajay K. , Jakubowiak, Andrzej , Yee, Andrew J , Siegel, David S. , Fonseca, Rafaël

Mayo Clinic

Journal of Clinical Oncology | January 30, 2018 | Volume: 36 | Issue: 9 | Pages: 859-866

10.1200/jco.2017.75.5207 | PMID 29381435 Get It

Purpose Selinexor, a first-in-class, oral, selective exportin 1 (XPO1) inhibitor, induces apoptosis in cancer cells through nuclear retention of tumor suppressor proteins and the glucocorticoid receptor, along with inhibition of translation of oncoprotein mRNAs. We studied selinexor in combination with low-dose dexamethasone in patients with multiple myeloma refractory to the most active available agents. Patients and Methods This phase II trial evaluated selinexor 80 mg and dexamethasone 20 mg, both orally and twice weekly, in patients with myeloma refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide (quad-refractory disease), with a subset also refractory to an anti-CD38 antibody (penta-refractory disease). The primary end point was overall response rate (ORR). Results Of 79 patients, 48 had quad-refractory and 31 had penta-refractory myeloma. Patients had received a median of seven prior regimens. The ORR was 21% and was similar for patients with quad-refractory (21%) and penta-refractory (20%) disease. Among patients with high-risk cytogenetics, including t(4;14), t(14;16), and del(17p), the ORR was 35% (six of 17 patients). The median duration of response was 5 months, and 65% of responding patients were alive at 12 months. The most common grade ≥ 3 adverse events were thrombocytopenia (59%), anemia (28%), neutropenia (23%), hyponatremia (22%), leukopenia (15%), and fatigue (15%). Dose interruptions for adverse events occurred in 41 patients (52%), dose reductions occurred in 29 patients (37%), and treatment discontinuation occurred in 14 patients (18%). Conclusion The combination of selinexor and dexamethasone has an ORR of 21% in patients with heavily pretreated, refractory myeloma with limited therapeutic options.
Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders
Hinson, Shannon R., López‐Chiriboga, A. Sebastian , Bower, James H., Matsumoto, Joseph Y., Hassan, Anhar , Basal, Eati, Lennon, Vanda A. , Pittock, Sean J. , McKeon, Andrew , Pittock, S J , McKeon, Andrew

Mayo Clinic

Neurology Neuroimmunology & Neuroinflammation | January 25, 2018 | Volume: 5 | Issue: 2 | Pages: No page available

10.1212/nxi.0000000000000438 | PMID 29464188 Get It

Intraregional model for end‐stage liver disease score variation in liver transplantation: Disparity in our own backyard
Croome, Kristopher P. , Lee, David D. , Burns, Justin M. , Taner, C. Burcin , Croome, Kris P , Lee, David D , Keaveny, Andrew P.

Mayo Clinic

Liver Transplantation | January 24, 2018 | Volume: 24 | Issue: 4 | Pages: 488-496

10.1002/lt.25021 | PMID 29365357 Get It

Variation in average Model for End‐Stage Liver Disease (MELD) score at liver transplantation (LT) by United Network for Organ Sharing (UNOS) regions is well documented. The present study aimed to investigate MELD variation at the interregional, intraregional, and intra–donation service area (DSA) levels. Patients undergoing LT between 2015 and 2016 were obtained from the UNOS standard analysis and research file. The distribution of allocation MELD score including median, skew, and kurtosis was examined for all transplant programs. Intraregional median allocation MELD varied significantly within all 11 UNOS regions. The largest variation between programs was seen in region 5 (MELD 24.0 versus 38.5) and region 3 (MELD 20.5 versus 32.0). Regions 1, 5, and 9 had the largest proportion of programs with a highly negative skewed MELD score (50%, 57%, and 57%, respectively), whereas regions 3, 6, 10, and 11 did not have any programs with a highly negative skew. MELD score distribution was also examined in programs located in the same DSA, where no barriers exist and theoretically no significant difference in allocation should be observed. The largest DSA variation in median allocation MELD score was seen in NYRT‐OP1 LiveOnNY (MELD score variation 11), AZOB‐OP1 Donor Network of Arizona (MELD score variation 11), MAOB‐OP1 New England Organ Bank (MELD score variation 9), and TXGC‐OP1 LifeGift Organ Donation Ctr (MELD score variation 9). In conclusion, the present study demonstrates that this MELD disparity is not only present at the interregional level but can be seen within regions and even within DSAs between programs located as close as several city blocks away. Although organ availability likely accounts for a component of this disparity, the present study suggests that transplant center behavior may also play a significant role.Liver Transplantation 24 488–496 2018AASLD.
Issues Surrounding Age-Adjusted d-Dimer Cutoffs That Practicing Physicians Need to Know When Evaluating Patients With Suspected Pulmonary Embolism
Goodwin, Andrew , Higgins, Russell A. , Moser, Karen , Smock, Kristi J. , Chandler, Wayne L. , Kottke‐Marchant, Kandice, Hartman, Sarah K., Volod, Oksana , Brown, Alan F., Johari, Vandita, Burr, Sharon, Polyakov, Nataliya, Chen, Dong , Goodwin, Andrew J, Moser, Karen A, Johari, Vandita P, Chen, Dong , Brown, Alan F.

Mayo Clinic

Annals of Internal Medicine | January 24, 2018 | Volume: 166 | Issue: 5 | Pages: 361-363

10.7326/m16-2030 | PMID 28024301 Get It

Mutations causing congenital myasthenia reveal principal coupling pathway in the acetylcholine receptor ε-subunit
Shen, Xin‐Ming , Brengman, Joan M., Shen, Shelley , Durmuş, Hacer , Preethish‐Kumar, Veeramani , Yüceyar, Nur , Vengalil, Seena , Deymeer, Feza , Sine, Steven M. , Engel, Andrew G. , Nalini, Atchayaram

Mayo Clinic

JCI Insight | January 24, 2018 | Volume: 3 | Issue: 2 | Pages: No page available

10.1172/jci.insight.97826 | PMID 29367459 Get It

We identify 2 homozygous mutations in the ε-subunit of the muscle acetylcholine receptor (AChR) in 3 patients with severe congenital myasthenia: εR218W in the pre-M1 region in 2 patients and εE184K in the β8-β9 linker in 1 patient. Arg218 is conserved in all eukaryotic members of the Cys-loop receptor superfamily, while Glu184 is conserved in the α-, δ-, and ε-subunits of AChRs from all species. εR218W reduces channel gating efficiency 338-fold and AChR expression on the cell surface 5-fold, whereas εE184K reduces channel gating efficiency 11-fold but does not alter AChR cell surface expression. Determinations of the effective channel gating rate constants, combined with mutant cycle analyses, demonstrate strong energetic coupling between εR218 and εE184, and between εR218 and εE45 from the β1-β2 linker, as also observed for equivalent residues in the principal coupling pathway of the α-subunit. Thus, efficient and rapid gating of the AChR channel is achieved not only by coupling between conserved residues within the principal coupling pathway of the α-subunit, but also between corresponding residues in the ε-subunit.
Utility of Pathology Imagebase for standardisation of prostate cancer grading
Egevad, Lars , Delahunt, Brett , Bostwick, David G., Cheville, John C. , Evans, Andrew , Fine, Samson W. , Grignon, David J. , Humphrey, Peter A. , Hörnblad, Jonas, Iczkowski, Kenneth A. , Kench, James G. , Leite, Kátia Ramos Moreira , McKenney, Jesse K. , Pan, Chin‐Chen , Samaratunga, Hemamali , Srigley, John R., Takahashi, Hiroyuki , True, Lawrence D. , Tsuzuki, Toyonori , Varma, Murali , Zhou, Ming , Clements, Mark , McKenney, Jesse K , Pan, Chin-Chen , Tsuzuki, Toyonori , Samaratunga, Hemamali , Berney, Daniel M. , Compérat, Éva , Kristiansen, Glen , Magi‐Galluzzi, Cristina , OXLEY, JON D. , Kwast, Theodorus van der

Mayo Clinic

Histopathology | January 23, 2018 | Volume: 73 | Issue: 1 | Pages: 8-18

10.1111/his.13471 | PMID 29359484 Get It

AimsDespite efforts to standardise grading of prostate cancer, even among experts there is still a considerable variation in grading practices. In this study we describe the use of Pathology Imagebase, a novel reference image library, for setting an international standard in prostate cancer grading.Methods and resultsThe International Society of Urological Pathology (ISUP) recently launched a reference image database supervised by experts. A panel of 24 international experts in prostate pathology reviewed independently microphotographs of 90 cases of prostate needle biopsies with cancer. A linear weighted kappa of 0.67 (95% confidence interval = 0.62–0.72) and consensus was reached in 50 cases. The interobserver weighted kappa varied from 0.48 to 0.89. The highest level of agreement was seen for Gleason score (GS) 3 + 3 = 6 (ISUP grade 1), while higher grades and particularly GS 4 + 3 = 7 (ISUP grade 3) showed considerable disagreement. Once a two‐thirds majority was reached, images were moved automatically into a public database available for all ISUP members at www.isupweb.org. Non‐members are able to access a limited number of cases.ConclusionsIt is anticipated that the database will assist pathologists to calibrate their grading and, hence, decrease interobserver variability. It will also help to identify instances where definitions of grades need to be clarified.
The unfolding landscape of the congenital myasthenic syndromes
Engel, Andrew G. , Shen, Xin‐Ming , Selcen, Duygu

Mayo Clinic

Annals of the New York Academy of Sciences | January 22, 2018 | Volume: 1413 | Issue: 1 | Pages: 25-34

10.1111/nyas.13539 | PMID 29355968 Get It

AbstractCongenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is impaired by one or more specific mechanisms. Since the advent of next‐generation sequencing methods, the discovery of novel CMS targets and phenotypes has proceeded at an accelerated rate. Here, we review the current classification of CMS and describe our findings in five of these targets identified and investigated in our laboratory in the past 5 years. Defects in LRP4 hinder synaptic development and maintenance; the defects in PREPL are predicted to diminish filling of the synaptic vesicle with acetylcholine; and defects in SNAP25, Munc13‐1, and synaptotbrevin‐1 impede synaptic vesicle exocytosis.